News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Myeloma Canada Says New Data At This Year’s Annual American Society of Hematology Meeting Offers A New Standard Of Care For Newly Diagnosed Multiple Myeloma Patients


12/10/2013 6:54:56 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Findings from a new study show continuous treatment with oral Revlimid® (lenalidomide) plus low-dose dexamethasone (Rd) improves survival and other measures of efficacy, compared to a standard of care for newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The findings are from the largest phase III global registration study ever conducted in newly diagnosed myeloma, including four Canadian centres, and were presented at the American Society of Hematology meeting in New Orleans, Louisiana, USA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES